Scientific Symposiums International Hot Topics, New Developments in Pancreatico-Biliary, Head and Neck, Lung and Genitourinary Pathology 2025

• Include:  videos +  pdf, size:  GB
• Target Audience: general surgical pathologists
• Sample video: contact me for sample video
• Information:

This is a four-day, high-level post-graduate course designed for practicing surgical pathologists. It focuses exclusively on four of the most challenging areas in diagnostic pathology: Pancreatico-Biliary, Head & Neck, Lung, and Genitourinary.

Hosted by Scientific Symposiums International, the course is structured to move beyond basic textbook definitions, addressing the “grey zones” and evolving classifications that pathologists face daily. It features a faculty of world-renowned experts (like Dr. David Klimstra and Dr. Bruce Wenig) who are arguably the leading authorities in their respective sub-specialties.

What You Will Learn

The curriculum focuses on practical diagnostic criteria and updates to WHO classifications. Key learning objectives include:

Diagnostic Precision: How to handle “borderline” cases where the distinction between benign and malignant has major treatment implications (e.g., pancreatic precursors, prostate grading).

Biomarker Integration: Understanding the 2025 guidelines for lung cancer biomarker testing and how to triage small specimens for molecular studies.

Pitfall Avoidance: Identifying histological “mimics” in the head and neck and GU tracts that often lead to misdiagnosis.

Reporting Standards: Implementing the latest grading systems for prostate and renal cancers to align with current oncological management.

Event Details

Course: Hot Topics, New Developments in Pancreatico-Biliary, Head and Neck, Lung and Genitourinary Pathology

Course Director: Stuart J. Schnitt, M.D. (Chief of Breast Oncologic Pathology, Dana-Farber/Brigham and Women’s Cancer Center)

Who Should Attend

General Surgical Pathologists: Who sign out a broad variety of cases and need to stay current across these four common but complex organ systems.

Senior Residents & Fellows: Preparing for boards or transition to independent practice.

Pathology Assistants (PAs): Interested in the clinical rationale behind specific grossing protocols for complex resections.

Why Attend

The “Giants” of Pathology: The faculty list includes legends in the field. Learning pancreatic pathology directly from Dr. David Klimstra or head and neck pathology from Dr. Bruce Wenig is a rare opportunity for direct interaction.

• Topics:

Monday, October 20

Gastroenteropancreatic Neuroendocrine Neoplasms: General Principles (David Klimstra M.D.)

Non-Ductal Neoplasms of the Pancreas (David Klimstra M.D.)

Follicular-Patterned Thyroid Lesions (Bruce Wenig M.D.)

An Update on Interstitial Lung Disease (Lynette Sholl M.D.)

Digital Slide Seminar: Challenging Diagnoses in Pancreatico-Biliary Pathology (David Klimstra M.D.)

Tuesday, October 21

Testicular Germ Cell Tumors: Focus on Diagnoses with Implications for Clinical Management (Andres Acosta M.D.)

Lung Nodules and Masses Other Than the Usual Suspects (Lynette Sholl M.D.)

The Diagnosis of Pancreatic-Ductal Adenocarcinoma and Its Precursors (David Klimstra M.D.)

The Pathology Evaluation of the Liver Tumor Biopsy (David Klimstra M.D.)

Digital Slide Seminar: Selected Cases in Head and Neck and Endocrine Pathology (Bruce Wenig M.D.)

Wednesday, October 22

Lung Cancer Diagnostic Updates (Lynette Sholl M.D.)

Salivary Gland Pathology (Bruce Wenig M.D.)

Sinonasal Tract Pathology (Bruce Wenig M.D.)

Prostate Cancer: Impact of Grading On Risk-Stratification, Highlighting Difficult and Unusual Gleason Patterns (Andres Acosta M.D.)

Digital Slide Seminar: Lung, Pleura and Mediastinum: Pathology Potpourri (Lynette Sholl M.D.)

Thursday, October 23

Squamous Cell Carcinoma of the Head and Neck (Bruce Wenig M.D.)

Urothelial Carcinoma: Divergent Differentiation and Histologic Subtypes with Impact on Treatment (Andres Acosta M.D.)

Morphologic and Immunophenotypic Characteristic of Common Renal Neoplasms and Dealing with Cases that Cannot Be Subclassified (Andres Acosta M.D.)

Lung Cancer Biomarker Testing: What You Need to Know in 2025 (Lynette Sholl M.D.)